The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy

• Váldodahkkit: Antonio Volpi (Dahkki), Sara Boccalini (Dahkki), Silvia Dari (Dahkki), Christopher Clarke (Dahkki), Desmond Curran (Dahkki), Idalba Loiacono (Dahkki), Andrea Pitrelli (Dahkki), Anna Puggina (Dahkki), Roberta Tosatto (Dahkki), Desirée Van Oorschot (Dahkki), Elisabetta Franco (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2020-02-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Herpes Zoster (HZ) presents a considerable public health burden in Italy among people aged ≥50 years. This study aimed to assess the clinical and economic impact of HZ vaccination in the 65 years of age (YOA) cohort in Italy, by comparing the new Adjuvanted Recombinant Zoster Vaccine (RZV) with the...